The potential of DNA vaccination against tumor-associated antigens for antitumor therapy

被引:44
|
作者
Haupt, K
Roggendorf, M
Mann, K
机构
[1] Univ Essen Gesamthsch, Dept Internal Med, Div Clin Chem, D-45122 Essen, Germany
[2] Univ Essen Gesamthsch, Inst Virol, D-45122 Essen, Germany
[3] Univ Essen Gesamthsch, Dept Internal Med, Div Endocrinol, D-45122 Essen, Germany
关键词
DNA vaccination; immunotherapy; tumor; immune response;
D O I
10.1177/153537020222700403
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Conventional treatment approaches for malignant tumors are highly invasive and sometimes have only a palliative effect. Therefore, there is an increasing demand to develop novel, more efficient treatment options. Increased efforts have been made to apply immunomodulatory strategies in antitumor treatment. In recent years, immunizations with naked plasmid DNA encoding tumor-associated antigens have revealed a number of advantages. By DNA vaccination, antigen-specific cellular as well as humoral immune reponses can be generated. The induction of specific immune responses directed against antigens expressed in tumor cells and displayed e.g., by MHC class I complexes can inhibit tumor growth and lead to tumor rejection. The improvement of vaccine efficacy has become a critical goal in the development of DNA vaccination as antitumor therapy. The use of different DNA delivery techniques and coadministration of adjuvants including cytokine genes may influence the pattern of specific immune responses induced. This brief review describes recent developments to optimize DNA vaccination against tumor-associated antigens. The prerequisite for a successful antitumor vaccination is breaking tolerance to tumor-associated antigens, which represent "self-antigens." Currently, immunization with xenogeneic DNA to induce immune responses against self-molecules is under intensive investigation. Tumor cells can develop immune escape mechanisms by generation of antigen loss variants, therefore, it may be necessary that DNA vaccines contain more than one tumor antigen. Polyimmunization with a mixture of tumor-associated antigen genes may have a synergistic effect in tumor treatment. The identification of tumor antigens that may serve as targets for DNA immunization has proceeded rapidly. Preclinical studies in animal models are promising that DNA immunization is a potent strategy for mediating antitumor effects in vivo. Thus, DNA vaccines may offer a novel treatment for tumor patients. DNA vaccines may also be useful in the prevention of tumors with genetic predisposition. By DNA vaccination preventing infections, the development of viral-induced tumors may be avoided.
引用
收藏
页码:227 / 237
页数:11
相关论文
共 50 条
  • [21] Immunoproteomics to identify tumor-associated antigens eliciting humoral response
    Mou, Zhirong
    He, Yujun
    Wu, Yuzhang
    CANCER LETTERS, 2009, 278 (02) : 123 - 129
  • [22] Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens
    Wagner, Sandra
    Mullins, Christina S.
    Linnebacher, Michael
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (48) : 5418 - 5432
  • [23] Tumor-associated carbohydrate antigens: A possible avenue for cancer prevention
    Xu, YF
    Sette, A
    Sidney, J
    Gendler, SJ
    Franco, A
    IMMUNOLOGY AND CELL BIOLOGY, 2005, 83 (04) : 440 - 448
  • [24] Combination of virotherapy with VSV and tumor vaccination significantly enhances the efficacy of antitumor therapy
    Sobhanimonfared, F.
    Bamdad, T.
    Sadigh, Z. A.
    Niko, H. R.
    Choobin, H.
    ACTA VIROLOGICA, 2018, 62 (04) : 394 - 400
  • [25] Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
    Yan, Ting
    Zhu, Lingfeng
    Chen, Jin
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [26] ADSORPTION OF A TUMOR-ASSOCIATED ANTIGEN ONTO CRYSTALIZED RAPAMYCIN NANOPARTICLES FOR COMBINED IMMUNO- AND ANTITUMOR THERAPY
    Pan, C. H.
    Yen, J. Y.
    Hsiao, Y. J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 38 - 38
  • [27] Intratumoral IL-12 Gene Therapy Results in the Crosspriming of Tc1 Cells Reactive Against Tumor-associated Stromal Antigens
    Zhao, Xi
    Bose, Anamika
    Komita, Hideo
    Taylor, Jennifer L.
    Kawabe, Mayumi
    Chi, Nina
    Spokas, Laima
    Lowe, Devin B.
    Goldbach, Christina
    Alber, Sean
    Watkins, Simon C.
    Butterfield, Lisa H.
    Kalinski, Pawel
    Kirkwood, John M.
    Storkus, Walter J.
    MOLECULAR THERAPY, 2011, 19 (04) : 805 - 814
  • [28] Antibodies specific for disease-associated antigens (DAA) expressed in nonmalignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention
    Jacqueline, Camille
    Finn, Olivera J.
    SEMINARS IN IMMUNOLOGY, 2020, 47
  • [29] In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma
    Rodeberg, David A.
    Erskine, Courtney
    Celis, Esteban
    JOURNAL OF PEDIATRIC SURGERY, 2007, 42 (08) : 1396 - 1402
  • [30] Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens
    Westdorp, Harm
    Skold, Annette E.
    Snijer, Berit A.
    Franik, Sebastian
    Mulder, Sasja F.
    Major, Pierre P.
    Foley, Ronan
    Gerritsen, Winald R.
    de Vries, I. Jolanda M.
    FRONTIERS IN IMMUNOLOGY, 2014, 5